AstraZeneca’s Andexxa has reached the endpoint of its study has made the decisi...
The recent rallying of Lilly’s market value has come as the result of two major ...
The FDA approval was supported by a double-blind, active comparator-controlled n...
The regulatory approval comes after a positive opinion issued by the European Me...
The company will now seek full-label approval for the bleeding reversal agent in...
Two EU agencies issued a statement on Covid-19 vaccine composition changes to in...
Shares rose for the company following data that favourably compares high-dose BX...
VAR 200 reduces renal cholesterol and the lipid accumulation that damages the fi...
The new pharmaceutical production facility will manufacture five billion tablets...
The sBLA was based on the prespecified interim analysis data from part one of th...
Acepodia has raised $259m in venture capital, including $109m in a Series C fina...
Foreign influences pose a significant, growing threat to the early-stage work th...
As Biogen’s new CEO Chris Viehbacher pores over Biogen’s books and scouts out M&...
“This is not ‘negotiation.’ It is tantamount to extortion,” Merck wrote in its s...
Merck sued the U.S. government, seeking an injunction to block the drug-price ne...
Oncologists accustomed to treating cancer with medicines have been slow to turn ...
